The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor
| Autor: | Igor A. Zolotukhin, I. S. Lebedev, E. Yu. Soldatsky |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Tachycardia
medicine.medical_specialty business.industry Hematology medicine.disease Confidence interval Surgery Dabigatran Venous thrombosis Hemorrhagic episodes Anesthesia medicine Routine clinical practice medicine.symptom Cardiology and Cardiovascular Medicine Adverse effect business Venous thromboembolism medicine.drug |
| Zdroj: | Flebologiia. 8:26 |
| ISSN: | 1997-6976 |
| DOI: | 10.17116/flebo20159126-29 |
| Popis: | the tolerance to dabigatran etexilate and the patients’ compliance with the prescribed treatment were estimated. Results. None of the patient exhibited the signs of recurrent venous thromboembolism (95% confidence interval 0—14.6%). Hemorrhagic episodes during the 3 month observation period were recorded in 4 (12.5%) patients (95% confidence interval 4—30%). The cases of severe hemorrhage were totally absent. Only one (3%) patient developed an adverse reaction (tachycardia). Compliance with the prescribed therapy was estimated at 94%. Conclusion. The application of dabigatran etexilate in the routine clinical practice has excellent prospects due to its high effectiveness and safety for the patients presenting with deep venous thrombosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|